Logo Clinical Practice Review and Meta-Analysis

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Clinical Practice Review and Meta-Analysis Logo Clinical Practice Review and Meta-Analysis Logo Clinical Practice Review and Meta-Analysis

27 May 2020 : Review article  

Overview of 8 Circulating MicroRNAs and Their Functions as Major Biomarkers for Cardiovascular Diseases

Changyi Chen1ABDEFG*, Jianming Lü1ABDEF, Zhengdong Liang1ABDEF, Dongliang Liu1ABDEF, Qizhi Yao12ABDEFG

DOI: 10.12659/CPRM.924530

Med Sci Rev 2020; 7:e924530


Intracellular microRNAs (miRNAs) can be released into extracellular compartments, thus entering into body fluids such as blood circulation. Circulating miRNAs are highly stable and considered as novel biomarkers for the diagnosis and/or prognosis of cardiovascular diseases (CVDs). There is a growing body of evidence supporting circulating miRNAs as prognosis and/or diagnosis biomarkers for CVDs. Using the signatures of circulating miRNAs could improve sensitivity and specificity as biomarkers for CVDs, including unstable angina, myocardial infarction, in-stent restenosis after coronary drug-eluting stents implantation, atrial fibrillation, and heart failure. Circulating miRNAs are associated with other traditional CVD biomarkers such as cardiac-specific troponin, myoglobin and creatine kinase-MB, and other CVD risk factors such as diabetes mellitus and hyperlipidemia. The present review is different with other review articles in that we provide detailed information for individual miRNAs, including both clinical and basic science data. We have selected the 8 miRNAs (miR-1, miR-21, miR-126, miR-133, miR-145, miR-208, miR-223, and miR-499) that are most studied and have shown major clinical value as biomarkers for CADs. The purpose of this review is to provide a full-spectrum overview of these miRNAs and to help clinicians/researchers to understand the clinical value of major circulating miRNAs and help them to design or participate in further investigations of these miRNAs, developing new technologies to improve health care for patients with CVDs.

Keywords: Cardiovascular Diseases, MicroRNAs, Myocardial Infarction

Add Comment 0 Comments

Most Viewed Current Articles

12 Nov 2021 : Review article  

A Review of the Effects of Transurethral Microwave Thermotherapy (TUMT) for Lower Urinary Tract Symptoms (L...

DOI :10.12659/CPRM.934690

Clin Prac Rev Met 2021; 8:e934690

10 Jan 2022 : Meta-Analysis  

Antiproteinase-3 (PR3)-Antineutrophil Cytoplasmic Atibody (ANCA) as a Predictor for Relapse in Antineutroph...

DOI :10.12659/CPRM.931261

Clin Prac Rev Met 2022; 9:e931261

21 Mar 2023 : Meta-Analysis  

Comparison of Next-Generation Sequencing Versus Culture-Based Tests for Sepsis Pathogens Detection in the I...

DOI :10.12659/CPRM.938643

Clin Prac Rev Met 2023; 10:e938643

07 Mar 2023 : Database Analysis  

Visual Analysis of Research Trends and Hotspots in Traditional Chinese Medicine-Based Treatment of Chronic ...

DOI :10.12659/CPRM.939445

Clin Prac Rev Met 2023; 10:e939445

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Clinical Practice Review and Meta-Analysis eISSN: 2688-6650
Clinical Practice Review and Meta-Analysis eISSN: 2688-6650